Compare ArcelorMittal SA (MT) vs TransMedics Group Inc (TMDX) Price & Performance

ArcelorMittal (MT) trades at $74.25, up 0.47% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings missed estimates, but revenue grew year-over-year, and the company maintains a positive outlook for H2 2026. Valuation ratios like P/S of 0.9 and P/B of 1.01 suggest reasonable pricing relative to sales and book value.

The outlook is cautiously optimistic with analyst consensus leaning Buy (50%) amid expectations of European business improvement and strategic expansions. Key risks include volatile steel demand, high capital expenditures, and macroeconomic pressures. Net cash flow remains negative, though operational cash generation is stable. Investors should weigh growth initiatives against cyclical industry headwinds.

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.